Home / Therapies / GLP-1 Agonist Therapy Center (page 10)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

Dr. Paresh Dandona, Part 1: GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes

Dr. Paresh Dandona, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Buffalo, The State University of New York, joins Associate Medical Editor Joy Pape in a discussion at the 2015 ADA Sessions in Boston regarding highlights of his presentation, "GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes."

Read More »